Articles
Stakeholders from across the pharmaceutical industry and beyond are joining the race to help develop a vaccine or therapeutic to combat the COVID-19 global threat. Alcimed outlines some key elements ...
Articles
Regular patient follow-up is key to improve medication adherence. To this end, digital tools provide a solution to help patients manage their treatments, from a simple reminder to take the treatment ...
Alcimed analyzes the different approved COVID-19 tests and highlights what kinds of tests can be deployed where to maximize information and resources regardless of where in the outbreak cycle a ...
Vertical farming holds huge promises for a sustainable future. Compared to traditional outdoor farming, vertical farms have lower land use requirement, less CO2 emissions from transportation if grown ...
Healthcare
The diagnostic and therapeutic potential of nanomedicine should result in an acceleration of its development in the following years. Alcimed goes back over the 4 main fields of application of ...
Healthcare
Following the International Rare Disease Day, Alcimed invites you to dive into the rare diseases’ universe, with a focus on patients and patient associations. To understand how they have become ...
Cross-sector
How can artificial intelligence benefit language preservation? Artificial intelligence (AI) makes it possible, through various applications, to preserve endangered languages and to decipher ancient ...
Articles
Zydus Cadila became the first pharmaceutical company to obtain a marketing authorization for Saroglitazar, a drug indicated for non-alcoholic steatosis of the liver (NASH), after getting the green ...
Articles
Tumor agnostic treatments are a very new development in the exciting field of personalized medicine. These drugs can be applied to tumors of any type targeting specific genomic anomalies or molecular ...
Healthcare
The difficulty to come up with therapeutic solutions for rare diseases, the emergence of resistance to certain drugs or pressure on the price of drugs urge pharma companies to rethink their R&D ...